Cargando…
Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection
Serous otitis media (SOM) occurs in children and constitutes one of the most significant causes of hearing loss in young age, posing as an important risk factor for long-term hearing loss. SOM is underdiagnosed, most frequently in infants, or the appointment to the ENT doctor is delayed due to non-a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713185/ https://www.ncbi.nlm.nih.gov/pubmed/34970348 http://dx.doi.org/10.3892/etm.2021.11048 |
_version_ | 1784623719691321344 |
---|---|
author | Mârțu, Cristian Cozma, Sebastian Cobzeanu, Bogdan Vesa, Doina Butnaru, Corina Bularda, Dragoș Cumpătă, Adeline Rădulescu, Luminița |
author_facet | Mârțu, Cristian Cozma, Sebastian Cobzeanu, Bogdan Vesa, Doina Butnaru, Corina Bularda, Dragoș Cumpătă, Adeline Rădulescu, Luminița |
author_sort | Mârțu, Cristian |
collection | PubMed |
description | Serous otitis media (SOM) occurs in children and constitutes one of the most significant causes of hearing loss in young age, posing as an important risk factor for long-term hearing loss. SOM is underdiagnosed, most frequently in infants, or the appointment to the ENT doctor is delayed due to non-acute symptomatology. The aim of the present study was to assess 285 patients with SOM diagnosed within a two-year span. The etiology and pathology of hearing loss in patients with different age groups were examined. The importance of a clinical examination and tympanometry was emphasized as absolutely necessary for a correct diagnosis. Treatment targeted Eustachian Tube permeabilization for satisfactory long-term middle ear aeration. Nasal drops with vasoconstrictor drugs (phenylephrine) and disinfectant (colloidal silver 1%) were commonly used, but some patients also benefitted from dexamethasone intratympanic injection. Patients were evaluated at the end of the treatment and follow-up occurred at one month, one year and three years later. |
format | Online Article Text |
id | pubmed-8713185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-87131852021-12-29 Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection Mârțu, Cristian Cozma, Sebastian Cobzeanu, Bogdan Vesa, Doina Butnaru, Corina Bularda, Dragoș Cumpătă, Adeline Rădulescu, Luminița Exp Ther Med Articles Serous otitis media (SOM) occurs in children and constitutes one of the most significant causes of hearing loss in young age, posing as an important risk factor for long-term hearing loss. SOM is underdiagnosed, most frequently in infants, or the appointment to the ENT doctor is delayed due to non-acute symptomatology. The aim of the present study was to assess 285 patients with SOM diagnosed within a two-year span. The etiology and pathology of hearing loss in patients with different age groups were examined. The importance of a clinical examination and tympanometry was emphasized as absolutely necessary for a correct diagnosis. Treatment targeted Eustachian Tube permeabilization for satisfactory long-term middle ear aeration. Nasal drops with vasoconstrictor drugs (phenylephrine) and disinfectant (colloidal silver 1%) were commonly used, but some patients also benefitted from dexamethasone intratympanic injection. Patients were evaluated at the end of the treatment and follow-up occurred at one month, one year and three years later. D.A. Spandidos 2022-02 2021-12-07 /pmc/articles/PMC8713185/ /pubmed/34970348 http://dx.doi.org/10.3892/etm.2021.11048 Text en Copyright: © Mârțu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Mârțu, Cristian Cozma, Sebastian Cobzeanu, Bogdan Vesa, Doina Butnaru, Corina Bularda, Dragoș Cumpătă, Adeline Rădulescu, Luminița Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection |
title | Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection |
title_full | Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection |
title_fullStr | Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection |
title_full_unstemmed | Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection |
title_short | Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection |
title_sort | serous otitis media: clinical and therapeutic considerations, including dexamethasone (c(22)h(29)fo(5)) intratympanic injection |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713185/ https://www.ncbi.nlm.nih.gov/pubmed/34970348 http://dx.doi.org/10.3892/etm.2021.11048 |
work_keys_str_mv | AT martucristian serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection AT cozmasebastian serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection AT cobzeanubogdan serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection AT vesadoina serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection AT butnarucorina serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection AT bulardadragos serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection AT cumpataadeline serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection AT radulesculuminita serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection |